|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating activities: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Stock-based compensation expense | |||||
| Lease expense | |||||
| Depreciation expense | |||||
| Net accretion of discount on marketable securities | |||||
| Amortization of premium on marketable securities | |||||
| Changes in operating assets and liabilities: | |||||
| Prepaid expenses and other current assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Other assets | |||||
| Net cash used in operating activities | |||||
| Investing activities: | |||||
| Purchases of property and equipment | |||||
| Purchases of marketable securities | |||||
| Maturities and sales of marketable securities | |||||
| Maturities of marketable securities | |||||
| Net cash provided by (used in) investing activities | |||||
| Financing activities: | |||||
| Proceeds from issuance of common stock, net of issuance costs | |||||
| Proceeds from exercise of stock options and warrants | |||||
| Net cash provided by financing activities | |||||
| Net increase in cash, cash equivalents and restricted cash | |||||
| Cash, cash equivalents and restricted cash at beginning of period | |||||
| Cash, cash equivalents and restricted cash at end of period | |||||
| Supplemental disclosure of non-cash investing and financing activities: | |||||
| Offering costs included in accounts payable and accrued expense | |||||
| Proceeds from exercise of stock options included in other current assets | |||||
| Leased assets obtained in exchange for new operating lease liabilities | |||||
Loading...